2.4.2.26	beta-mercaptoethanol	XT-II activity is completely abolished at a concentration 1% (v/v) beta-mercaptoethanol	773	
2.4.2.26	CDP	23% residual activity at 10 mg/ml	212	
2.4.2.26	CMP	45% residual activity at 10 mg/ml	100	
2.4.2.26	Co2+	Co2+ reduces activity by more than 60% at 5 mM	23	
2.4.2.26	CTP	8% residual activity at 10 mg/ml	60	
2.4.2.26	Cu2+	enzyme activity is abolished by Cu2+	19	
2.4.2.26	Cu2+	complete inhibition at 5 mM	19	
2.4.2.26	dithiothreitol	XT-II activity is completely abolished at a concentration of 1 mM dithiothreitol	45	
2.4.2.26	Glycosaminoglycans	associate with the enzyme	46733	
2.4.2.26	heparin	-	227	
2.4.2.26	heparin	non-competitive inhibitor using fragment(1-24) of human basic fibroblast growth factor as xylose acceptor	227	
2.4.2.26	additional information	competitive inhibition of the acceptor substrates	2	
2.4.2.26	additional information	no inhibition by CDP	2	
2.4.2.26	additional information	-	2	
2.4.2.26	additional information	lysozyme does not change the activity of XT-II at any concentration	2	
2.4.2.26	additional information	reduced total XylT activity in sera from mice possessing visible tumors as compared to controls	2	
2.4.2.26	N-Phenylmaleimide	treatment shows no effect on wild-type XT-I but strongly inactivaets the cysteine mutants C461A and C574A	3831	
2.4.2.26	Ni2+	enzyme activity is abolished by Ni2+	38	
2.4.2.26	Ni2+	complete inhibition at 5 mM	38	
2.4.2.26	protamine	adding protamine to a final concentration of 10 mg/ml decreases XT-II activity 4fold	1289	
2.4.2.26	UDP	inhibition on the XT-I activity of C561A mutant enzyme is significantly reduced compared with all other tested cysteine mutants	26	
2.4.2.26	UDP	-	26	
2.4.2.26	UDP	5% residual activity at 10 mg/ml	26	
2.4.2.26	UMP	25% residual activity at 10 mg/ml	133	
2.4.2.26	UTP	4% residual activity at 10 mg/ml	65	
2.4.2.26	Zn2+	strong	14	
2.4.2.26	Zn2+	enzyme activity is abolished by Zn2+	14	
2.4.2.26	Zn2+	complete inhibition at 5 mM	14